2.06

0.49% 0.01

After Hours: 2.02 -0.04 -1.94%

Akebia Therapeutics Inc (AKBA)

Overview News Price History Option Chain Financials Discussions Forecast

Akebia Therapeutics Inc stock is traded at $2.06, with a volume of 1.61M. It is up +0.49% in the last 24 hours and up +29.56% over the past month. Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Previous Close:

$2.05

Open:

$2.05

24h Volume:

1.61M

Relative Volume:

0.89

Market Cap:

$447.27M

Revenue:

$194.75M

Net Income/Loss:

$-51.26M

P/E Ratio:

-3.9615

EPS:

-0.52

Net Cash Flow:

$-23.38M

1W Performance:

+15.08%

1M Performance:

+29.56%

6M Performance:

+87.27%

1Y Performance:

+108.04%

1-Day Range:

$2.03

$2.08

1-Week Range:

$1.75

$2.10

52-Week Range:

$0.80

$2.48

Akebia Therapeutics Inc Stock (AKBA) Company Profile

Name

Akebia Therapeutics Inc

Sector

Healthcare (1200)

Industry

Drug Manufacturers - Specialty & Generic (87)

Phone

617-871-2098

Address

245 FIRST STREET, CAMBRIDGE, MA

Employee

167

Twitter

@akebiatx

Next Earnings Date

2024-11-07

Latest SEC Filings

AKBA's Discussions on Twitter

Compare AKBA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AKBA Akebia Therapeutics Inc	2.06	447.27M	194.75M	-51.26M	-23.38M	-0.52
ZTS Zoetis Inc	176.74	80.59B	9.15B	2.43B	2.31B	4.92
HLN Haleon Plc Adr	9.72	44.17B	14.26B	1.55B	0	0.3327
TAK Takeda Pharmaceutical Co Adr	13.57	42.61B	30.27B	1.93B	3.45B	0.444
TEVA Teva Pharmaceutical Industries Ltd Adr	16.57	18.77B	16.77B	-959.00M	1.37B	-2.00
VTRS Viatris Inc	13.22	15.73B	15.05B	-883.30M	1.89B	1.53

Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-29-23	Resumed	BTIG Research	Buy
Aug-28-23	Upgrade	H.C. Wainwright	Neutral → Buy
May-31-23	Upgrade	Piper Sandler	Neutral → Overweight
Mar-31-22	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-31-22	Downgrade	Mizuho	Buy → Neutral
Mar-31-22	Downgrade	Needham	Buy → Hold
Mar-31-22	Downgrade	Piper Sandler	Overweight → Neutral
Mar-08-21	Initiated	Cantor Fitzgerald	Overweight
Jan-29-21	Downgrade	JP Morgan	Neutral → Underweight
Nov-14-19	Reiterated	Needham	Buy
Aug-06-19	Reiterated	H.C. Wainwright	Buy
Jul-11-19	Reiterated	H.C. Wainwright	Buy
May-02-19	Initiated	JP Morgan	Overweight
Mar-20-19	Initiated	Citigroup	Neutral
Sep-07-18	Resumed	Morgan Stanley	Equal-Weight
Aug-10-18	Reiterated	Needham	Buy
Jun-06-18	Reiterated	H.C. Wainwright	Buy
Dec-19-17	Initiated	Piper Jaffray	Overweight
Dec-07-17	Initiated	BTIG Research	Buy
Sep-15-17	Initiated	RBC Capital Mkts	Sector Perform
Jul-10-17	Reiterated	H.C. Wainwright	Buy
Apr-27-17	Reiterated	H.C. Wainwright	Buy
Apr-27-17	Reiterated	Needham	Buy
Dec-27-16	Reiterated	H.C. Wainwright	Buy
Dec-20-16	Reiterated	JMP Securities	Mkt Outperform
Nov-15-16	Initiated	Aegis Capital	Buy
Sep-29-16	Initiated	Brean Capital	Buy
Mar-16-16	Reiterated	Needham	Buy
Jan-21-16	Initiated	Credit Suisse	Neutral

View All

Akebia Therapeutics Inc Stock (AKBA) Latest News

Nov 25, 2024

Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference - StreetInsider.com

Nov 25, 2024

Akebia Therapeutics CEO to Present at Piper Sandler Healthcare Conference | AKBA Stock News - StockTitan

Nov 25, 2024

Nov 23, 2024

Akebia Therapeutics to Present at the Jefferies London Healthcare Conference - GuruFocus.com

Nov 23, 2024

Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - GuruFocus.com

Nov 23, 2024

Vadadustat Alternative Dosing Study Results Published in the Ame - GuruFocus.com

Nov 23, 2024

AKBA (Akebia Therapeutics) Future 3-5Y Total Revenue Growth Rate : 9.95 (As of Nov. 23, 2024) - GuruFocus.com

Nov 23, 2024

Nov 22, 2024

Akebia Therapeutics to Report Third Quarter 2024 Financial Resul - GuruFocus.com

Nov 22, 2024

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listi - GuruFocus.com

Nov 22, 2024

Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply C - GuruFocus.com

Nov 22, 2024

Akebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024 - GuruFocus.com

Nov 22, 2024

Nov 20, 2024

Q3 2024 Earnings: Hold Akebia Therapeutics (NASDAQ:AKBA) - Seeking Alpha

Nov 20, 2024

Nov 14, 2024

Akebia's FDA-Approved Vafseo Shows Promise in Key Dialysis Trial Results | AKBA Stock News - StockTitan

Nov 14, 2024

Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease - Victoria Advocate

Nov 14, 2024

Nov 13, 2024

Akebia Therapeutics (NASDAQ:AKBA) Stock Rating Lowered by StockNews.com - Defense World

Nov 13, 2024

Nov 09, 2024

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 09, 2024

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$5.50 - Yahoo Finance

Nov 09, 2024

Nov 08, 2024

Earnings call: Akebia reports Q3 results, gears up for Vafseo launch - Investing.com Australia

Nov 08, 2024

Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Price Is Right But Growth Is Lacking After Shares Rocket 41% - Simply Wall St

Nov 08, 2024